Stockscreener 앱 받기
3.50
0.00%
0.00
시장 영업 전:
3.50
Cyclerion Therapeutics Inc 주식(CYCN)의 최신 뉴스
Cyclerion Therapeutics Inc (CYCN) Institutional Confidence - TradingKey
Cyclerion Therapeutics Inc (CYCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cyclerion Therapeutics, Inc. SEC Filing (Jul 27, 2026) - Stock Titan
Cyclerion Therapeutics Inc (CYCN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cyclerion Therapeutics Inc (CYCN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cyclerion Therapeutics, Inc. Revenue Breakdown – NASDAQ:CYCN - TradingView
Cyclerion Therapeutics Inc (CYCN) Balance Sheet - TradingKey
CYCN|Cyclerion Therapeutics Inc|Price:3.370|Chg%:-0.130 - TradingKey
CYCN|Cyclerion Therapeutics Inc|Price:3.440|Chg%:-0.060 - TradingKey
Cyclerion Therapeutics Inc (CYCN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CYCN|Cyclerion Therapeutics Inc|Price:3.475|Chg%:-0.025 - TradingKey
Cyclerion Therapeutics Inc (CYCN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RKLBRocket Lab Stock Price Today, News, Analysis and Trading Ideas - Stocktwits
Cyclerion Therapeutics (CYCN) plans merger with Korsana and $380M financing - Stock Titan
Form 13D/A CYCLERION THERAPEUTICS For: 21 July By Investing.com - Investing.com South Africa
Cyclerion Therapeutics (CYCN) investor reports 19.4% stake and preferred share conversion - Stock Titan
Cyclerion Therapeutics (CYCN) director converts 351,037 preferred to common shares - Stock Titan
Cyclerion Therapeutics Inc. (CYCN) Q4 2025 Earnings: EPS Beats Estimates as Pre-Revenue Biotech Tightens Cost ControlProfit Recovery Report - dars.gov.et
Cyclerion Therapeutics (CYCN) Retreats 1.9% as Stock Tests Crucial Support ZoneIV Spike - dars.gov.et
Cyclerion Therapeutics (NASDAQ: CYCN) to merge with Korsana in $380M financing deal - Stock Titan
Cyclerion Therapeutics to merge with Korsana Biosciences (KRSA) after $380M pre-closing financing - Stock Titan
Cyclerion Therapeutics (CYCN) Presses Lower: Support Test in FocusETF Creation Redemption - dars.gov.et
Cyclerion Therapeutics (CYCN) Gains 6.6% as Shares Test Key Resistance Near $3.55PCR Spike - dars.gov.et
Enterprise value to revenue forward of Cyclerion Therapeutics, Inc. – NASDAQ:CYCN - TradingView
Price to sales forward of Cyclerion Therapeutics, Inc. – NASDAQ:CYCN - TradingView
Cyclerion Therapeutics,Inc. Actuals & Estimates (NASDAQ:CYCN) - TradingView
Cyclerion Therapeutics (CYCN) Faces Resistance as Shares Slide Nearly 4%Put Support - dars.gov.et
Cyclerion Therapeutics (CYCN) Edges Higher as Stock Tests Key ResistanceTriple MA Cross - DonanımHaber
Cyclerion Therapeutics Inc (CYCN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cyclerion Therapeutics Inc (CYCN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cyclerion Therapeutics Inc (CYCN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cyclerion Therapeutics, Inc. announced that it has received $200 million in funding - marketscreener.com
Cyclerion Therapeutics (CYCN) Hovers Near $3.00 as Low Volume Caps MovementDark Pool Volume - newsline.com
Cyclerion (NASDAQ: CYCN) to Merge with Korsana, $380M Pre-Closing Financing - Stock Titan
CYCN Q4 2025 Earnings: Narrowed Loss Surpasses Estimates Amid Pipeline ProgressEarnings Outlook Update - newsline.com
Cyclerion Therapeutics stock soars 350% on Korsana merger, $380 million financing - MSN
Cyclerion Therapeutics (CYCN) Edges Higher Amid Quiet TradingCash Flow Strong Stocks - The Legal Advocate
CYCN Q4 2025 Earnings: Narrowed Losses Exceed Expectations as Development Programs ProgressPre-Earnings Drift - The Legal Advocate
RKTO Stock Price and Chart — NASDAQ:RKTO - TradingView
Cyclerion Therapeutics Company Profile & Introduction - Moomoo
CYCN - Finviz
Cyclerion Therapeutics (CYCN) Edges Higher as Shares Test Key Resistance LevelsRounding Bottom - The Legal Advocate
Cyclerion Shares to Watch With Deal in Focus as Markets Reopen - Bez Kabli
CYCN Q4 2025 Earnings: Narrowed Loss Beats Street Estimates, Shares ClimbAnnual Report - newsline.com
Cyclerion (CYCN) Delivers Q4 2025 Beat — EPS $-0.21 vs $-0.39 ExpectedTangible Book Value - newsline.com
Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Korsana deal and cash crunch reshape Cyclerion (NASDAQ: CYCN) outlook - Stock Titan
TradingKey - TradingKey
CYCN News | CYCLERION THERAPEUTICS INC (NASDAQ:CYCN) - ChartMill
Why Cyclerion (CYCN) deserves a deeper look right now (-2.78%) 2026-05-07Insider Info - newser.com
FMR LLC holds 15.0% of Cyclerion Therapeutics (NASDAQ: CYCN) in Schedule 13G - Stock Titan
1.97%
0.83%
자본화:
|
볼륨(24시간):